Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2...

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Amplified c-erbB-2 gene copies and subsequent overexpression of the erbB-2 receptor are common in human breast and ovarian tumors.
• The cell surface localization and high expression of erbB-2 make it a suitable target for targeted cancer therapies.

Purpose of the Study:

• To develop a targeted cancer therapy using a recombinant fusion protein that specifically binds to the human erbB-2 receptor.
• To evaluate the efficacy of this fusion protein in inhibiting tumor cell growth and protein synthesis.

Main Methods:

• Recombinant DNA technology was employed to create a single-chain antibody-exotoxin A (scFv-ETA) fusion protein.
• The scFv portion was derived from a monoclonal antibody recognizing the extracellular domain of the erbB-2 receptor.
• The fusion protein's binding, protein synthesis inhibition, and cytotoxicity were assessed in vitro and in vivo models.

Main Results:

• The bacterially produced scFv-ETA protein demonstrated specific binding to cells expressing the human erbB-2 protein.
• scFv-ETA inhibited protein synthesis in erbB-2-expressing tumor cells at doses of 2-200 ng/ml.
• Equivalent doses of scFv-ETA were cytotoxic to these tumor cells, and in vivo studies showed inhibited tumor growth in mice.

Conclusions:

• The scFv-ETA fusion protein is a specific and effective agent against erbB-2-overexpressing tumors.
• This targeted therapy holds potential for treating breast and ovarian cancers.
• Further investigation into scFv-ETA as a therapeutic strategy is warranted.